Exelixis takes Cipla to court over generic cancer drug

21-03-2023

Liz Hockley

Exelixis takes Cipla to court over generic cancer drug

rafapress / Shutterstock.com

Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.


Exelixis, Cipla, Cabometyx, cabozantinib, patents, MSN Laboratories, cancer treatment

LSIPR